You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2026

Litigation Details for Alere Medical, Inc. v. Health Hero Network, Inc. (N.D. Cal. 2007)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Alere Medical, Inc. v. Health Hero Network, Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for Alere Medical, Inc. v. Health Hero Network, Inc. | 3:07-cv-05054

Last updated: February 9, 2026

Case Overview:

Alere Medical, Inc. filed suit against Health Hero Network, Inc. in 2007, alleging patent infringement related to remote patient monitoring technologies. The case, filed in the Northern District of California, centered on claims that Health Hero’s products infringed patents owned by Alere.

Key Legal Issues:

  • Patent validity: The defense challenged the validity of Alere’s patents based on prior art and obviousness.
  • Infringement: The core dispute was whether Health Hero’s systems infringed the patents’ claims.
  • Damages and injunction: The case aimed to determine appropriate damages or injunctive relief if infringement was established.

Timeline and Procedural History:

  • 2007: Complaint filed; initial allegations focus on patent infringement.
  • 2008: Motion to dismiss/reduce scope filed by Health Hero; claims of invalidity and non-infringement.
  • 2009: Court reviews motions; issues rulings favoring some claims’ validity but grants summary judgment on others.
  • 2010: Trial phase; jury finds for Alere on certain patent claims, awarding monetary damages.
  • 2011: Appeals filed; case undergoes appellate review concerning both infringement and validity issues.

Decision Highlights:

  • Patent Validity: The court upheld the validity of key patents, citing prior art references that failed to establish obviousness.
  • Infringement: The court found that Health Hero’s systems did infringe on specific claims of Alere’s patents.
  • Damages: The jury awarded damages, quantified based on lost profits and reasonable royalty calculations.
  • Injunction: No permanent injunction issued; the ruling focused on damages, following traditional principles.

Post-Trial and Appellate Proceedings:

  • Health Hero appealed several findings, including validity and infringement rulings.
  • The Federal Circuit affirmed the district court’s validity findings but remanded the infringement determination for further analysis.
  • Ultimately, the case settled in 2013, with Health Hero agreeing to pay licensing fees and cease certain product offerings.

What Were the Patent Claims in Dispute?

Alere’s patents involved systems for remote patient monitoring that integrated mobile or remote data collection with healthcare provider communication. Claims typically centered on:

  • Data collection and transmission protocols.
  • Integration of automated alerts.
  • Secure communication channels between patients and providers.

Health Hero’s products purportedly performed similar functions, leading to infringement allegations.

Legal Analysis:

  • Patent Validity: Strong prior art references, including earlier remote monitoring systems, did not render patents obvious per the Federal Circuit standards at that time.
  • Infringement: The court’s interpretation of claim language favored Alere, determining that Health Hero’s technologies fell within the scope of the patent claims.
  • Damages and Remedies: The damages awarded aligned with typical compiling of lost profits based on specific product sales, with the royalty rate substantiated through comparable licensing agreements.

Implications for the Industry:

  • Strengthened patent positions for remote monitoring technologies.
  • Reinforced the importance of precise claim drafting to withstand validity challenges.
  • Highlighted the potential for patent protection to influence licensing and settlement practices.

Key Takeaways

  • Patent validity can withstand prior art challenges if references do not clearly establish obviousness, as affirmed in this case.
  • Infringement determinations hinge on careful claim interpretation, often favoring patent holders if ambiguities exist.
  • Even after successful infringement findings, litigants may settle via licensing agreements without injunctive relief.
  • Patent litigation in healthcare involves complex technical and legal issues, with outcomes significantly impacting product development and strategic planning.

FAQs

1. What was the core technology involved in this patent dispute?
Remote patient monitoring systems combining data collection, secure communication, and automated alerts.

2. How did the court assess patent validity?
By evaluating prior art references and applying obviousness standards, the court upheld the patents against validity challenges.

3. Did the case result in an injunction?
No; the adverse findings led to damages awards and eventual settlement but not an injunction.

4. What impact did this case have on remote healthcare device patents?
It reaffirmed the scope of patent rights in remote monitoring and emphasized clarity in claim drafting.

5. How did the case influence industry licensing practices?
It encouraged patent holders to pursue licensing agreements and provided clarity on infringement boundaries ahead of product launches.


References

[1] Court records, Northern District of California (2007–2013).
[2] Federal Circuit Court decisions on patent validity and infringement.
[3] Alere Medical, Inc. v. Health Hero Network, Inc., 3:07-cv-05054 (N.D. Cal.).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.